Core Viewpoint - The company reported significant growth in revenue and net profit for the fiscal year 2025, driven by overseas market expansion and recovery in the domestic biopharmaceutical industry [1] Financial Performance - The company achieved operating revenue of RMB 1.379 billion, representing a year-on-year increase of 40.63% [1] - The net profit attributable to the owners of the company was RMB 173 million [1] - The net profit attributable to the owners of the company, excluding non-recurring gains and losses, was RMB 116 million [1] Strategic Initiatives - The company's growth was supported by a strategy focused on innovation, with sustained high levels of R&D investment to build core technological barriers [1] - The company emphasized lean management to continuously improve operational efficiency, contributing to rapid enhancement of profitability [1]
百奥赛图-B(02315.HK)业绩快报：2025年度营收增长超4成，实现归母净利润达1.73亿元